BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

AbSorber AB Announces New CEO


4/17/2008 7:10:31 AM

STOCKHOLM, Sweden--(BUSINESS WIRE)--Anders Karlsson has been appointed the new CEO of LinkMed’s portfolio company AbSorber. Karlsson has been COO of the company since the fall 2007. AbSorber’s former CEO Ingemar Lagerlöf, who is also CEO of LinkMed, is taking on the role of member of the board of AbSorber.

“Anders Karlsson has done an excellent job since he joined AbSorber in the fall. He demonstrated early on that he has the drive that is necessary for the company to achieve success in the complex transplantation market,” says LinkMed’s CEO, Ingemar Lagerlöf.

“My goal is to establish AbSorber as an innovative, world leading supplier in the transplantation sector. Our portfolio provides us with excellent potential to achieve this goal,” says Anders Karlsson.

Karlsson has extensive experience from the pharmaceutical industry. He has previously worked in the transplantation sector and was the CEO of Novartis in Norway.

AbSorber develops products that facilitate more successful transplantations. Today, AbSorber has one commercial product, a standardized transplantation test XM-ONE®, used to evaluate organ transplantation risk. AbSorber has entered into a global sales agreement for XM-ONE® with the U.S. medtech company BD. AbSorber is also developing an ABO column to facilitate organ transplantations between people of different blood groups and a diagnostic test that measures the occurrence of blood group antigens. The company was established in 1999 to commercialize findings from research carried out by professors Jan Holgersson and Suchitra Holgersson at the Karolinska University Hospital, in Huddinge, outside Stockholm.

LinkMed owns 42.1 percent of AbSorber.

LinkMed develops life-science companies in collaboration with innovators. By contributing entrepreneurship and capital, LinkMed has created a portfolio of twelve companies, six in drug development and biotechnology and six in medical technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm and the company’s largest partners are FastPartner, Koncentra Holding and the founder Ingemar Lagerlöf. See www.linkmed.se for more information.

This information was brought to you by Cision http://newsroom.cision.com

Contact:

LinkMed Ingemar Lagerlöf, CEO, +46 8 508 939 93

Source: LinkMed

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->